Cambridge Isotope Laboratories and Nexomics Biosciences Sign an Exclusive Worldwide Commercial Supply Agreement

Scientific research, guided by stable isotope-enriched protein reagents, has become commonplace in academic and biopharmaceutical research. CIL and Nexomics will address this demand by producing and offering catalog and custom isotope-enriched proteins.

Under the terms of the agreement, Nexomics will provide protein-production services, while CIL will provide global sales and marketing support. “We are very excited to enter into agreement with CIL, one of the most respected names in the field of stable isotope reagents for biomedical research. These reagents have a wide range of applications. In addition to producing catalog proteins, our extensive experience in producing isotope-enriched proteins will be invaluable to our clients,” says Gaetano Montelione, CEO of Nexomics Biosciences. 

“Nexomics’ success in developing techniques to determine protein structure using nuclear magnetic resonance (NMR) spectroscopy nicely complements CIL’s mission to offer isotope-enriched reagents used to produce labeled recombinant protein. The capabilities that Nexomics offers, such as the production and NMR analysis of isotope-enriched protein, will enhance and expand CIL’s current product offering,” says Joel Bradley, CEO of CIL.

About Nexomics Biosciences, Inc. 
Nexomics Biosciences is a contract research organization (CRO), offering a broad array of gene-to-structure services to the biopharmaceutical community. By utilizing a fully integrated protein  structure production pipeline, Nexomics can offer a variety of services from bioinformatics, target profiling, gene cloning, recombinant protein expression, laboratory-scale fermentation, crystallization, NMR structural studies, X-ray crystallographic  structural studies, target validation, and functional annotation. For more information about Nexomics Biosciences, visit nexomics.com.